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Simple Summary: This study proposes a novel strategy in brain cancer management. Stereotactic
radiosurgery delivered by the Gamma Knife was combined with hyperthermia. For the radiobio-
logical modelling of this synergistic treatment modality, we used the linear-quadratic model with
temperature-dependent parameters to assess the potential enhancement of the therapeutic outcome.
The results indicate that focused intracranial heating can be used to boost the dose to the target.
Alternatively, one can conclude that for the same therapeutic effect, hyperthermia can help to min-
imize the dose undesirably delivered to healthy tissues. This study is also the first to advocate a
combination of stereotactic radiosurgery with focused heating and motivates the future development
of hyperthermia systems for brain cancer treatment.
Abstract: Combining radiotherapy (RT) with hyperthermia (HT) has been proven effective in the
treatment of a wide range of tumours, but the combination of externally delivered, focused heat and
stereotactic radiosurgery has never been investigated. We explore the potential of such treatment
enhancement via radiobiological modelling, specifically via the linear-quadratic (LQ) model adapted
to thermoradiotherapy through modulating the radiosensitivity of temperature-dependent parame-
ters. We extend this well-established model by incorporating oxygenation effects. To illustrate the
methodology, we present a clinically relevant application in pediatric oncology, which is novel in two
ways. First, it deals with medulloblastoma, the most common malignant brain tumour in children, a
type of brain tumour not previously reported in the literature of thermoradiotherapy studies. Second,
it makes use of the Gamma Knife for the radiotherapy part, thereby being the first of its kind in
this context. Quantitative metrics like the biologically effective dose (BED) and the tumour control
probability (TCP) are used to assess the efficacy of the combined plan.
Keywords: stereotactic radiotherapy; hyperthermia; CNS tumors; medulloblastoma; biological
modelling; LQ model
1. Introduction
Central nervous system (CNS) tumours constitute the second most common form
of cancer in children [1]. Improved treatment protocols have increased survival rates to
more than 80% [2]. However, the treatment may have multiple, debilitating side effects,
so-called late effects or late complications. Radiotherapy (RT) is an essential treatment
modality in the clinical management of brain tumours and vascular malformations, but it is
also most prone to cause late complications. Long-term neurocognitive sequelae are often
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severe in paediatric patients, where 50–96% of the treated individuals display intellectual
impairments [3,4]. Methods such as proton therapy and stereotactic treatments with
photons are becoming increasingly popular, especially in children, because of their potential
to deliver a dose limited to the target and thus reduce RT-related toxicity.
Hyperthermia (HT) is defined as an induced temperature increase in tumours to about
40–44 ◦C for typically 60 min. It has been demonstrated that hyperthermia (HT) improves
local control for a wide range of tumours and can increase overall survival rates in patients
treated with radiotherapy (RT) [5–9] or chemotherapy [10,11]. For instance, despite the
technically challenging delivery of HT to the head and neck (H&N) region, HT offers a
valuable treatment option for patients with tumours in this region [12]. A meta-analysis
study of H&N carcinomas, recently published in [7], shows that the complete response rate
(CR) in patients treated with combined radiotherapy and hyperthermia (RTHT) appears to
be significantly better than that of the patients treated with RT alone (RT alone: CR = 39.6%
vs. RTHT: CR = 62.5%). At the same time, acute and late-grade 3/4 toxicities have not
been reported to be significantly different between two arms [7]. Although most of the
patients treated with hyperthermia have been adults, encouraging clinical results also exist
for children and adolescents [13]. The combination of chemotherapy and hyperthermia has
been successfully applied in children with refractory or recurrent non-testicular malignant
germ cell tumours. The long-term prognosis for patients with poor response or after the
first relapse is similar to the prognosis for those receiving first-line treatment [14].
The clinical experiences with HT applied for brain cancer treatment are limited to
high-grade glioblastomas (GBM). The interstitial HT combined with radiotherapy has been
demonstrated to be a safe [15–17] and promising modality to improve the survival of the
patients. In a two-arm study, Sneed et al. [18] have shown a two-year survival rate of 31% in
the arm with HT versus 15% in the arm without HT. Despite the promising results in terms
of an improved treatment outcome, homogeneous tumour temperatures were difficult to
achieve with the interstitial applicators used [15,18]. As an adjuvant for RT, intratumoral
injection of magnetic nanoparticles in magnetic hyperthermia therapy has also been shown
to improve survival rate in GBM, compared to the therapeutic outcomes achieved with RT
alone [19]. More recently, a localised increase of tumour temperature has been achieved
through magnetic fluid HT [20], in which injected iron oxide nanoparticles are excited by
an externally applied AC magnetic field. Again, the higher overall survival of patients
in the arms including HT was observed [21]. Another technology with promising results
in moderate heating in small animal tumours is the high-intensity focused ultrasound
(HIFU) [22]. The present HIFU technology has not yet been proven feasible for the heating
of large volumes typical for childhood brain tumours.
Our work is based on microwave phased array technology [23,24] that has been
the most widely applied technology for the treatment of deep-seated tumours in clini-
cal settings. However, this technology has not been applied intracranially before due to
several challenges. The high perfusion rates in the brain quickly normalise the temper-
ature and thus require the application of strong electromagnetic (EM) fields to achieve
adequate tumour temperatures. Moreover, the presence of electrically highly conductive
cerebrospinal fluid (CSF) leads to considerable absorption of EM radiation, thereby mak-
ing CSF more susceptible to the emergence of treatment-limiting hot spots. However,
recently published numerical studies [25–29] suggest that the intracranial heating with
those innovative approaches is feasible. A particularly unique approach is a helmet-like
configuration that utilises UWB antennas, allowing for better focusing with fewer antennas
than standard annular-phased-array applicators [30]. Using a thermodynamic fluid model
of CSF, the study demonstrated that this type of applicator is capable of obtaining an
adequate temperature in large brain tumours without inducing unacceptable hot spots [31].
In current clinical practice, HT is typically delivered in combination with external
beam radiation therapy (EBRT), which strongly relies on the fact that normal tissues
are generally better at sublethal DNA damage repair than tumour tissues. Therefore,
numerous dose fractionation schemes, in the order of 30 fractions delivered over a period
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of 5–10 weeks, have been exploited [32]. In comparison, stereotactic radiosurgery (SRS)
aims to achieve a therapeutic effect by using a single or few fractions to deliver a highly
conformal dose. Since its invention, the Leksell Gamma Knife® (Elekta AB, Stockholm,
Sweden) models have been used to sculpt the dose to conform to the target. The dose
gradient outside the target is sharp, with little impact on surrounding healthy tissues
and organs at risk. The SRS delivery is often limited to small target volumes, since its
application for medium-sized and large tumours eradication would lead to an unfeasible
increase in the treatment time.
In this study, we propose a novel strategy in brain cancer management, combining
hyperthermia with SRS delivered by the Gamma Knife. The hypothesis is that focused
microwave heating of a tumour will boost the radiotherapeutic effect or alternatively allow
for a reduced radiation dose without compromising the treatment outcome. The potential
treatment enhancement is investigated via radiobiological modelling, specifically via
the linear-quadratic (LQ) model adapted to thermoradiotherapy through modulating
the radiosensitivity of temperature-dependent parameters [33,34]. The model is further
extended with an oxygen modification factor (OMF) that includes the effect of the local
oxygen tension, pO2 [35]. The model is applied to evaluate the expected increase of the
therapeutic window when hyperthermia is added to SRS. The combined effect is assessed
on a medium-sized paediatric brain tumour. The methodology proposed in this work can
be considered as a framework for the evaluation of the combined effect of thermal therapy
and radiosurgery.
2. Materials and Methods
2.1. Patient Model
An MRI scan with a 1× 1× 1 mm resolution was obtained from a 13-year old boy with
medulloblastoma. The scan was manually segmented by a clinician into 10 tissue types,
as visualized in Figure 1. Only a part of the head was segmented, and the section outside
the treatment volume, that is, the part of the head below the tumour that was not covered
by the applicator was modelled as muscle. Observe that the volume of the original tumour,
as studied in [31], has been reduced to 34 mL by means of morphological operations
(erosion). The volume no longer occupied by the tumour has been filled with a mirrored
copy of the opposite healthy brain hemisphere to preserve the anatomical correctness.
In the context of the current proof-of-concept study, this may be considered a valid model
for various residual brain tumours, such as medulloblastomas or ependymomas.
Electromagnetic and thermal simulations are performed using tissue parameters from
the IT’IS database [36] adjusted for hyperthermic conditions: muscle perfusion is increased
by a factor of 4 due to the systemic response to heat [37], while the thermal conductivity of
the cerebrospinal fluid is increased by a factor of 10 to emulate the convective transport of
heat [31]. Tumour properties are obtained as an average of grey and white matter, and its
blood perfusion is decreased by a factor of 0.7 to account for the chaotic vasculature [38].
Due to the frequency dependence of the dielectric properties and utilisation of multiple
frequencies in the treatment planning phase, the properties are not listed here. Nevertheless,
the tissue properties listed in [31] can be considered as an example for 450 MHz.
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Figure 1. Cross-section of the patient model along with the tissue indices. Border of the tumour is
shown with the solid black line.
2.2. Hyperthermia Treatment Planning with Novel Applicator
The hyperthermia applicator consists of eight self-grounded bow-tie antennas im-
mersed into a separate water bolus [39] and arranged in a helmet-shaped array. A water
bolus is inserted between the antennas and the patient for skin-cooling and impedance-
matching. Four antennas operate across the frequency band of 400∼800 MHz, while the
others are upscaled to operate at lower frequencies of 300∼600 MHz. The applicator is thus
designed for multi-frequency treatments, and the set of operating frequencies considered
for this study is 300, 400, 500, 600, 700, and 800 MHz. Each antenna is excited by a periodic
signal resulting from the superposition of all the individual frequencies. Each frequency
component is independently steered in phase and amplitude for each antenna.
The antenna arrangement within the applicator is obtained via a global optimization
procedure based on a specific absorption rate (SAR) that, conjointly for each antenna,
determines the location and polarization angle to minimize the hot-spot to target quotient
(HTQ) [40]. The procedure has been introduced in [41] and subsequently extended for
use with the non-linear cost function HTQ and for the multi-frequency ultra-wideband
(UWB) range adopted in this study. The steering parameters, that is, the phase and
amplitude of each antenna at each operating frequency, are obtained via particle swarm
optimization [42], using the HTQ as the cost function. The final antenna arrangement
is visualized in Figure 2. The temperature distribution is then obtained by scaling the
power deposition until the threshold for thermal damage in healthy brain temperatures
(42 ◦C) [43] is reached. The temperature of the water bolus is set to 10 ◦C. The quality and
feasibility of the treatment plan are evaluated in terms of the indexed temperatures T10,
T50 and T90, which represent the temperatures achieved in 10, 50, and 90% of the target
volume, respectively.
(a) Front (b) Left (c) Right (d) Top
Figure 2. Helmet applicator optimized for the thermal treatment of the tumour considered in this
study. The red cones indicate the feed point and polarization direction of each antenna. The blue
shade indicates water.
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2.3. Stereotactic Radiosurgery Treatment Planning
The Gamma Knife models, Leksell Gamma Knife Icon® IconTM and Leksell Gamma
Knife® PerfexionTM (Icon, Perfexion), deliver dose from 192 Cobalt-60 sources that are
collimated into narrow beams by a large tungsten body, see, for example, [44]. The beams
converge in a small volume, called the isocenter, about 40 cm from the sources. The sources
are housed within eight sectors with 24 sources in each sector. The sectors can slide
over the collimator body, which in total has 576 collimator channels, in four different
positions to produce beams of sizes of 4, 8 and 16 mm (The sizes refer to the cross-sectional
diameters of single beams at the isocenter). The fourth position is beam-off when only a
negligible amount of radiation leaks through the tungsten body. For each isocenter there
are 65,535 different beam size combinations, colloquially called “shots”. By shifting the
position of the patient, a dose is delivered to several isocenters. The total dose can thus be
sculpted to conform to the target with a sharp dose gradient outside the target, leading to a
small dose to healthy tissue and organs at risk.
To create a dose plan, patient images are imported to the treatment-planning software
Leksell GammaPlan® (LGP). In LGP, the target and organs at risks (OAR) are outlined,
and the shots are placed in the target and weighted relative to each other to create an
adequate dose distribution. The dose plan to the tumour described above was created by
the new optimization tool, Leksell Gamma Knife® Lightning. By specifying the prescription
dose to the target, max dose constraints on OARs, and optimization weights, a plan with a
reasonable trade-off between quality and beam-on-time (BOT) is determined.
For this particular case no specific OAR is outlined, instead bringing down the dose
to the tissue surrounding the target is promoted. Furthermore, achieving a plan with good-
quality metrics was considered to be the most important objective, and hence less emphasis
was put on bringing down the BOT. In Table 1 the quality metrics and beam-on-time are
given for this plan. For definitions of radiosurgical metrics, see [45]. Note that achieving
high target dose homogeneity is seldom an objective in Gamma Knife surgery. On the
contrary, for most plans, the prescription dose at the periphery of the target corresponds to
40–60% of the max dose in the target. This is to ensure a sharp dose gradient at the target
periphery leading to a rapid fall-off of the dose. In this particular case, the relative isodose
of 60% was chosen by the optimizer.
Table 1. Metrics for the medulloblastoma plan.
Prescription Dose Coverage Selectivity Gradient Index Beam-on Time (min) @ 3 Gy/min Number of Shots
15 Gy 0.994 0.850 2.63 54.8 110
2.4. Radiosensitivity Modelling
The overall cell survival of the combined therapy can be described by a generalised LQ
model that includes both direct cytotoxicity and a radiosensitising effect of hyperthermia.
The cell survival is expressed as a function of temperature (T) and radiation dose (D), as
well as the time interval between the two therapies:
SF(D, T, tint) = SFHT(T)× SFRT(D, T, tint), (1)
where SFHT is the term referring to cell-killing due to direct hyperthermic cytotoxicity,
while SFRT accounts for cell-killing due to radiation. tint is the time interval between the
end of radiotherapy and the start of hyperthermia treatment in the range of [0–4] h.
SFHT can be modeled using the Arrhenius relationship [46]:
SFHT(T) = exp[−K(T)× tH ], (2)
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where tH is the heating time (in this case 1 h) and K is the reaction rate as a function of
temperature T (◦C), given by [33]:







where ∆H (cal/mol) is the inactivation energy of the critical rate-limiting molecules which
are responsible for cell death, and ∆S (cal/◦C/mol) is the entropy of inactivation.
For the SFRT part, the extended LQ model, which considers the radiosensitising effect
of HT, is used to describe the cell killing due to radiotherapy, according to [33]
SFRT(D, T, tint) = exp
(
− α(T, tint)× D− G× β(T, tint)× D2
)
, (4)
with G as the protraction factor as defined in Section 2.5 and
α(T, tint) = α37 × exp
(
T − 37






β(T, tint) = β37 × exp
(
T − 37






where µ (h−1) is the rate at which the radiosensitizing effect of hyperthermia disappears,
α37 = α(37, 0), α41 = α(41, 0), β37 = β(37, 0), and β41 = β(41, 0).
In this study, we applied parameters for a generic head and neck (H&N) tumour [47],
as reported in Table 2. The parameters for healthy tissues are same as tumour parameters
with two distinctions: (a) at normothermic temperatures α37/β37 = 3 Gy, a ratio which
is well-established, (b) µ = 1 h−1 as the radiosensitising effect tends to disappear faster
in normal tissue than in tumorous tissue [48]. The alpha and beta ratios at elevated
temperatures, that is, α41/α37 and β41/β37, are kept the same as for the tumour model since
we could not find any experimental data for them in the literature.
Table 2. Parameters for the model in Equation (4).
Parameters Tumour Healthy Tissue
α37 (Gy−1) 0.35 0.35
α37/β37 (Gy) 10 3
α41/α37 2.36 2.36
β41/β37 0.53 0.53
µ (h−1) 0.047 1
∆S (cal/◦ C/mol) 423.14 423.14
∆H (cal/mol) 157,312.3 157,312.3
The Oxygen Effect
The cell survival model, as described in the preceding section, considers that all the
cells in the population are well-supplied with oxygen, hence a fully oxic cell population.
To assess the effect of molecular oxygen on the irradiated tissue, the oxygen enhancement
ratio (OER) is defined as the ratio of radiation dose in hypoxia to that of in well-oxygenated
conditions. Based on OER, oxygen modification factors (OMF) being dependent on both
the local oxygen tension (pO2) and the duration of hypoxia (thyp) can be incorporated in









Cancers 2021, 13, 3277 7 of 16
In this study, it was assumed that the cell oxygenation is not changing during the
course of the treatment. Hence, only the pO2 effect has been taken into account and the






where k is a reaction constant of 2.5–3 mmHg [50,51], while OERmax is the maximum
protection achieved in the absence of oxygen which is considered to be 3 here.
The oxygenation of the tumour depends on its vasculature, which is chaotic and
irregular [52]. Tumours are often characterized by a poorly oxygenated core due to the lack
of blood vessels reaching the deeper layers that are surrounded by regions of progressively
increased oxygenation towards the tumour periphery. To investigate the impact of oxy-
genation effect on the outcome of combined HT and SRS treatment, three cases have been
considered: a well-oxygenated tumour, a moderately oxygenated tumour, and a poorly
oxygenated tumour. The tumour was segmented into several iso-distance layers from
the periphery inwards as shown in Figure 3a and a degree of oxygenation was allocated
to each layer from a set of three distributions of oxygen partial pressure in tissue [53],
Figure 3b. Figure 3c visualizes the resulting distributions of oxygen partial pressure in the
considered models.
(a)
5 10 15 20 25 30 35


























Figure 3. Modelling of the oxygenation level in the tumour. (a) A transverse cut of the iso-contour
from the surface of the tumour. (b) Clinically representative histograms of pO2 for a generic tumour
under three different hypoxic conditions. (c) Mapped pO2 distribution for those that are well-,
moderately-, and poorly-oxygenated, respectively, from left to right.
2.5. Evaluation of Effect of the Combined Treatment
In order to quantify the impact of combined treatment, we consider two metrics:
the equivalent normalized total dose (EQD) and biological effective dose (BED). Al-
though these two metrics are related to each other, a clear distinction between them is
necessary. Supposing an SRS schedule with n fractions of equal size, complete repair
between fractions, and negligible repair during the fractions, the protraction factor is given
by G = 1/n. The EQD can then be calculated by solving the following equation
SF(EQD) = SF(D, T, tint), (10)
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α237 + 4Gβ37 × [α(T, tint)× D + G× β(T, tint)× D2 + K(T)× tH ]
2Gβ37
, (11)
where α(T, tint) and β(T, tint) are given in Equations (7) and (8), respectively. The BED
given for the fractionated plan with d f rac as the dose per fraction is then calculated using
BED = EQD× RE where RE stands for relative effectiveness given by RE = 1 + d f racα/β [47].
In our analysis, we further considered tumour control probability (TCP), an additional
metric that estimates the probability that a tumour will be eradicated or controlled by the
thermoradiotherapy. In particular, the TCP describes the probability with which cancer










where NT is the total number of voxels in tumour and ni = n is the number of clono-
genic cells.
The potential effect of the combined treatment on the normal brain tissue is evaluated
by assessing the clinically relevant parameter V10 volume. The V10 volume is defined as the






Hence, in the forthcoming analysis, V10 is defined as a region with BED ≥ 43 Gy, and its
estimation is limited to the resolution of the voxel model, that is, 1 (mm3).
3. Results
The hyperthermia treatment plan was obtained by using the SAR optimization proce-
dures, which resulted in HTQ values of 1.5 and excellent tumour coverage TC25 = 98%.
The resulting steady-state temperature distribution, visualized in Figure 4a, was then ob-
tained by scaling the power deposition with hard constrains for normal tissue temperature
of 42 ◦C. The temperature distribution is visualized in the sagittal plane of the patient
model, with the tumour delineated by a solid black line. Note that only temperatures above
37 ◦C are shown for better visualization. Temperatures below 37 ◦C are caused by the
surface cooling water bolus and do not have any impact on the analysis of the combined RT
+ HT effect. The main hot-spot (i.e., the tissue temperature 42 ◦C) is located in the pocket of
cerebrospinal fluid caudal to the target volume. The achieved T90 = 39.0 ◦C, T50 = 39.8 ◦C
and T10 = 40.4 ◦C indicate adequate tumour coverage by the thermal dose.
The Gamma Knife treatment plan with the prescribed dose of 15 Gy resulted in 99.4%
coverage, as reported in Table 1, and BED of 37.5 Gy when delivered in a single fraction.
Given the size of the target, this treatment plan resulted in an unacceptably high V10 of
43 cm3. In order to mitigate this issue, a five-fraction scheme is considered in the analysis.
Observe that we used a simple, uncompensated scheme where the original treatment dose
is maintained despite the fractionation. The compensation is considered later in this section.
In all cases of the fractionated scheme, we assume that HT is delivered after each RT fraction,
provided that the time between the RT fractions is long enough to allow for sublethal
damage reparation and for prevention of development of the thermotolerance [55,56].
The BED distribution corresponding to the five-fraction scheme is visualized in Figure 4b.
One can observe a sharp dose gradient around GTV that is characteristic of SRS treatments.
The boosting effect of adjuvant hyperthermia on the BED is illustrated on two cases:
heat applied to fully oxic tumour directly after irradiation (Figure 4c) and heat applied to
poorly oxygenated tumour four hours after radiation (Figure 4d). These cases represent the
extreme values of the enhanced BED achieved for all considered cases shown in Figure 5.
In both cases, the thermoradiotherapy plan resulted in a substantially higher BED to the
GTV than the radiosurgery-only plan.
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Figure 5 summarizes in detail the estimated biological effective radiation dose of
the combined thermoradiotherapy treatment plan (RT + HT) achieved for different oxy-
genation conditions and sequential administration. The black lines represent the results
for radiation only, while the coloured lines represent the combined treatment adminis-
tered with time interval 0 (solid coloured lines) and 4 h after irradiation (dashed coloured
lines). Although the results suggest a noticeable increase in the BED values for all lev-
els of oxygenation, the administration of HT directly after RT, that is, Tint = 0, yields a
bigger boost for each oxygenation level. Furthermore, the highest BED is observed for
the oxic population, followed by the estimated BED for well-, moderately-, and poorly-
oxygenated scenarios.
As a result of fractionation, the BED inevitably decreases. In order to achieve the
same therapeutic outcome for the target, specified by the BED = 37.5 Gy, the radiation dose
needs to be magnified by an appropriate scale factor, which increases with an increased
number of fractions. To assess the effect of fractionation as well as to quantify the impact
of the combined plan outside GTV, the V10 values for three fraction schemes and two
RT + HT time intervals are reported in Figure 6. Observe that the reported fractionated
plans are compensated by their respective scaling factors to give the same BED in the target
as a single fraction scheme. The combined administration of HT with RT reduces the V10
volume, and this reduction is pronounced with an increased number of fractions. In a
five-fraction scheme, the V10 volume is reduced from 30 cm3 to approximately 17 cm3 for
both time intervals of 0 and 4 h.
(a) Hyperthermia Temperature (◦C) (b) BED, RT-alone, Oxic
(c) BED, Oxic, Tint = 0 (d) BED, Poorly-oxygenated, Tint = 4
Figure 4. The thermal and BED distributions in the sagittal plane (a) Temperature distribution.
(b) BED for RT plan with the total dose of 15 Gy delivered in five-fractions (c) BED of the combined
plan for the well-oxygenated tumour and sequential administration with Tint = 0 (d) BED of the
combined plan for the poorly oxygenated tumour and HT administration 4 h after RT.
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Figure 5. BED-Volume histograms for thermoradiotherapy plan with a total dose of 15 Gy given in
five fractions.
Figure 6. V10 for compensated plans so that even with fractionation, we can still achieve BED equal
to 37.5 Gy for 99.4% of the voxels in the target.
Finally, the results in terms of TCP are shown in Figure 7. The TCP for the combined
HT and RT is shown in comparison with the TCP for RT alone in the range of [0.5–0.8]
and denoted by TCP0. In particular, TCP0 is based on the assumption that the radiosensi-
tivity of all the cells in the tumour is described by the generic parameters derived in oxic
conditions, as given in Table 2. The TCP is calculated for the RT + HT treatment through
Equation (12) assuming an average clonogenic cell density determined from TCP0. Again,
the results are presented for different oxygenation conditions and for time intervals of 0 and
4, respectively (Figure 7a,b). The RT + HT combined plans, represented by dashed lines,
exhibit substantially higher TCP than the corresponding RT alone curves. Furthermore,
the enhanced effect of combined treatment is more pronounced for cells in hypoxic condi-
tions. The impact of the time interval between the RT and HT is not prominent, as TCP
values of the combined plans for both time intervals exhibit the TCP above 0.9 in all cases.
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Figure 7. TCP at time intervals (a) 0 h and (b) 4 h.
4. Discussion
In this methodological study, we implemented the LQ model adapted for thermora-
diotherapy [33] and determined clinically relevant parameters for assessing the combined
effect of SRS and mild hyperthermia. We further extended the original model by oxy-
gen modification factor [49]. That way, we could account for the well-known ability of
hyperthermia to enhance tumour radiosensitivity.
Focused intracranial heating is challenging due to strict constrains on maximum
temperatures of 42 ◦C [57,58]. The patient specific applicator design along with the
multi-frequency treatment planning resulted in adequate tumour coverage represented by
T90 = 39.0 ◦C, T50 = 39.8 ◦C and T10 = 40.4 ◦C. The size of the target, 34 cc, is considered
to be a large volume for a Gamma Knife treatment, and therefore, many shots were required
to reach high-quality metrics, such as coverage, selectivity, and gradient index. The new
inverse planner for Gamma Knife treatments, Leksell Gamma Knife® Lightning, leads
to plans with more shots than manual planning. Lightning often generates plans with
more than one shot in a given isocenter to enhance the dose sculpting properties, which is
reflected in Table 1. Note that although many shots are used, the beam-on-time for this
large target is not particularly long.
The original, single fraction Gamma Knife treatment plan specified by the BED of
37.5 Gy, corresponding to a prescription dose of 15 Gy, gives a V10 of 43 cm3. Since a large
V10 volume has been found to correlate to adverse cognitive effects, see, for example, [59],
we used a five-fraction scheme in the analysis of the boosting effect of thermal therapy.
Furthermore, we could show that the combined administration of HT with RT can halve
the V10 volume in a five-fraction scheme while maintaining the BED in the target. In certain
cases, such as in multi-organ metastasis treatments, the size of the low dose volume V10 is
a highly relevant parameter for treatment planning. In these cases, organs at risk (OAR)
are often delineated and inspected specifically for the delivered dose levels.
A significant improvement of the examined parameters, that is, the BED and TCP,
was achieved for the combined treatment, indicating a beneficial effect of elevated tumour
temperatures. However, it must be stated that the calculated quantitative gains might be af-
fected by the uncertainties in reported values of LQ parameters. Uncertainties in the values
of α, β, and α/β, categorized typically by tumour sites, are generally large. In the absence
of more specific values, we applied parameters for a generic, early reacting tumour [47].
This is a conservative approach which assumes that the cells are rapidly proliferating and
hence have a higher sensitivity to fractionation. A similar strategy was used in previous
modelling studies that assessed the trend of the investigated parameters related to the
tumour response such as BED and TCP instead of actual quantitative estimates of these
parameters [60]. The α41/α37, β41/β37 were kept the same for both tumour and healthy
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tissues, as those parameters are unknown for healthy tissue cells. Recently, the thermal
dependence of cervical tumour cell lines SiHa and HeLa was experimentally determined
by in vitro studies [33,34]. A difference between in vitro and in vivo for some parameters,
α/β ratio in particular, is anticipated. Since the difference between the radiobiological
parameters for brain tumour cell lines might be even larger than that of cervical cell lines,
the results achieved in this study are illustrative.
Furthermore, these results can still be considered as a conservative assessment of
the enhanced effect associated with hyperthermia. The LQ model and its extensions do
not consider important features of hyperthermia, such as modulation of immunologic
responses or changes in tumour microenvironment. In particular, an increased blood flow
is expected to enhance the killing effect in hypoxic tumours.
The impact of the time interval between radiotherapy and hyperthermia delivery,
in terms of both TCP and BED, appears less important than expected from reviews of radio-
biological studies [61,62]. Nevertheless, the enhanced effect appears consistent for different
hypoxic conditions. In the context of technological requirements for sequential administration,
this is a positive observation that strengthens the combined therapy’s feasibility.
The main impact of this study, apart from demonstrating the potential application
of thermoradiotherapy in brain tumour management, is the guidance for evaluation and
quantification of the common biological effect of both therapies. Kok et al. [63] suggested
the use of equivalent radiation dose (EQD) instead of the cell survival model. We propose
to direct the analysis towards the BED, which provides a more straightforward clinical
insight and is often used for clinical decisions [64]. Furthermore, for the SRS, we recom-
mend applying the second-order equation to calculate the EQD instead of the first-order
solution proposed by [33,65]. Given that dose distributions of SRS are typically more
inhomogeneous than that of EBRT, our approach avoids any approximation and thus yields
more precise results.
In this study, the combined treatment is demonstrated on a paediatric tumour. How-
ever, the use of the Gamma Knife stereotactic radiosurgery (SRS) is not limited by the age of
the patients. Rather, the Gamma Knife SRS is widely used in the treatment of both children
and adults, primarily when the number of tumours is limited and their volumes small
(ideally < 2 cubic centimetres). In pediatric patients, it is important to minimize the dose to
the surrounding healthy tissue and thus to reduce the risk of late complications. In adult
patients, the Gamma Knife SRS, potentially in combination with hyperthermia, can be
particularly useful in the treatment of tumour residues, meningiomas, or metastases.
5. Conclusions
This study is the first to propose a methodological concept that evaluates a treatment
plan combining stereotactic radiosurgery with microwave hyperthermia. Radiosensiti-
sation has been modelled using an extended version of the LQ model with temperature-
dependent radiosensitivity parameters and an oxygen modification factor. The results
presented in terms of clinically relevant parameters, BED, V10 and TCP, indicate that the
focused intracranial heating can be used either to boost the dose to the GTV area or to
minimize the dose given to healthy tissues while maintaining the therapeutic effect de-
scribed by BED. The estimated tumour control can be significantly improved by adjuvant
hyperthermia. However, the results should not be seen in terms of absolute gain as they
are achieved for this particular and generic case of radiosensitivity parameters.
This study is also the first to advocate a combination of stereotactic radiosurgery
with focused heating. It motivates the future development of hyperthermia systems for
brain cancer treatment to facilitate clinical trials and validate the effects of the combined
treatment. Moreover, the methodological concept proposed here is independent of the form
of RT or HT delivery. Therefore, a similar assessment can be performed for virtually any
treatment; both EBRT and SRS plans can be applied, as well as heating by other focused
delivery modalities, such as ultrasound.
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